Yusuf Hamied
| Yusuf Hamied | |
|---|---|
 | |
| Lahir | 25 Juli 1936 Wilno, Provinsi Wilno, Polandia (kini Vilnius, Lithuania) |
| Kebangsaan | India |
| Pendidikan | Christ's College, Cambridge |
| Kekayaan bersih | US$1.59 miliar (Februari 2018)[1] |
| Gelar | Ketua Cipla |
| Pengganti | M. K. Hamied |
| Suami/istri | Farida |
| Anak | tidak ada |
| Orang tua | Khwaja Abdul Hamied, Luba Derczanska |
| Penghargaan | Padma Bhushan |
| Penghargaan
| |
Yusuf Khwaja Hamied (lahir 25 Juli 1936) adalah seorang ilmuwan dan pengusaha miliuner India yang menjabat sebagai ketua Cipla, sebuah perusahaan obat generik yang didirikan oleh ayahnya Khwaja Abdul Hamied pada 1935.[2] Ia juga terpilih menjadi anggota Akademi Sains Nasional India.[3]
Referensi
- ^ "Yusuf Hamied". Forbes. Diakses tanggal 25 February 2018.
- ^ Sarah Boseley (2003-02-18). "Yusuf Hamied, generic drugs boss | World news". The Guardian. London. Diakses tanggal 2010-09-01.
- ^ "Fellows Elected 2019" (PDF). Indian National Science Academy. Diarsipkan dari asli (PDF) tanggal 2 August 2019. Diakses tanggal 2 August 2019.
Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.